# Safety and Efficacy of Nabilone in Alzheimer's Disease

> **NCT02351882** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 38 (actual)

## Conditions studied

- Alzheimer Disease
- Agitation
- Weight Loss
- Pain
- Oxidative Stress

## Interventions

- **DRUG:** Nabilone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02351882
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2018-01
- **Final completion:** 2019-03
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02351882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02351882, "Safety and Efficacy of Nabilone in Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02351882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*